MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. (MAIA) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · MAIA · as of Sep 30, 2025
Ownership Breakdown
19
Institutional Holders
▼ 1 vs Q2
$3.49M
Total Inst. Value
▼ $465,123 vs Q2
60.80M
Shares Outstanding
freeFloat 131.55%
2.37M
13F Shares Held
▲ 89,449 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
MAIA largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VANGUARD GROUP INC pharmaceutical preparations | 1.10M | 3.64% | 3.64% | $1.70B | Nov 7, 2025 | ▼ 37.6K |
CENTRIC WEALTH MANAGEMENT pharmaceutical preparations | 574.9K | 1.90% | 1.90% | $712.87M | Nov 4, 2025 | ▲ 1.5K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 271.1K | 89.46% | 89.46% | $417.53M | Nov 12, 2025 | ▲ 48.9K |
MARSHALL WACE, LLP pharmaceutical preparations | 110.5K | 36.46% | 36.46% | $170.12M | Nov 13, 2025 | ▲ 94.3K |
BLACKROCK, INC. pharmaceutical preparations | 104.9K | 34.61% | 34.61% | $161.48M | Nov 12, 2025 | ▲ 1.6K |
STATE STREET CORP pharmaceutical preparations | 75.5K | 24.93% | 24.93% | $116.35M | Nov 14, 2025 | — held |
NORTHERN TRUST CORP pharmaceutical preparations | 39.0K | 12.88% | 12.88% | $60.11M | Nov 14, 2025 | — held |
BRIDGEWAY CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 36.0K | 11.88% | 11.88% | $55.44M | Nov 14, 2025 | — held |
CENTERPOINT ADVISORY GROUP pharmaceutical preparations | 15.7K | 5.19% | 5.19% | $24.22M | Nov 4, 2025 | — held |
WEALTH ENHANCEMENT ADVISORY SERVICES, LLC pharmaceutical preparations | 14.8K | 4.88% | 4.88% | $26.49M | Oct 29, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
6
Increased
+160.1K shares2
New Positions
first time holders3
Decreased
−42.1K shares4
Sold Out
fully exitedNet shares change (top 50)
+118.0K
+160.1K / −42.1K
Net new holders
+1
2 new / 4 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
MAIA insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
9
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Vitoc Vlad Chief Executive Officer | Jun 1, 2026 | Purchase | 72,700 | $1.39 | $100.9K | 976.1K | Form 4 ↗ |
Smith Stan director | Jun 1, 2026 | Purchase | 75,000 | $1.34 | $100.2K | 1.52M | Form 4 ↗ |
Gryaznov Sergei Chief Scientific Officer | Jun 1, 2026 | Purchase | 2,000 | $1.34 | $2.7K | 46.5K | Form 4 ↗ |
Vitoc Vlad Chief Executive Officer | May 29, 2026 | Award | 800,000 | $1.39 | $1.11M | 800.0K | Form 4 ↗ |
Gryaznov Sergei Chief Scientific Officer | May 29, 2026 | Award | 400,000 | $1.39 | $556.0K | 400.0K | Form 4 ↗ |
Himmelreich Jeffrey C Head of Finance | May 29, 2026 | Award | 60,000 | $1.39 | $83.4K | 60.0K | Form 4 ↗ |
Vitoc Vlad Chief Executive Officer | Apr 10, 2026 | Award | 800,000 | $1.28 | $1.02M | 800.0K | Form 4 ↗ |
Gryaznov Sergei Chief Scientific Officer | Apr 10, 2026 | Award | 400,000 | $1.28 | $512.0K | 400.0K | Form 4 ↗ |
Himmelreich Jeffrey C Head of Finance | Apr 10, 2026 | Award | 30,000 | $1.28 | $38.4K | 30.0K | Form 4 ↗ |
CHAOUKI STEVEN M director | Mar 31, 2026 | Award | 27,907 | $1.40 | $39.1K | 27.9K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
MAIA Biotechnology, Inc. (MAIA) is primarily owned by institutional investors, who hold approximately 3.9% of total shares outstanding. Company insiders own approximately 0.00%, while retail and public investors account for the remaining 127.65%.
The largest institutional shareholder of MAIA Biotechnology, Inc. is VANGUARD GROUP INC, holding approximately 1.10 million shares — equal to 3.64% of outstanding shares — as of September 30, 2025.
A total of 19 institutional investors currently hold MAIA stock, with a combined institutional value of approximately $3,487,006 as of the most recent 13F filing period.
Frequently asked questions
MAIA ownershipMAIA Biotechnology, Inc. (MAIA) is primarily owned by institutional investors, who hold approximately 3.9% of shares. The largest shareholder is VANGUARD GROUP INC with a 3.64% stake. Company insiders hold 0.00%. Data sourced from SEC Form 13F as of September 30, 2025.